Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII.
Hemophilia A is a X-linked bleeding disorder that is caused by the functional absence of blood coagulation factor VIII. The bleeding tendency in hemophilia A patients can be corrected by the administration of plasma-derived or recombinant factor VIII concentrates. A serious complication in hemophilia care is the development of factor VIII neutralizing antibodies (inhibitors) that arise as a consequence of factor VIII replacement therapy. The majority of factor VIII inhibitors are directed toward epitopes located within the A2, A3, and C2 domains of factor VIII. In this article, we summarize current knowledge on the epitope specificity of factor VIII inhibitors. In addition, we will discuss recent information on the molecular characteristics of human anti-factor VIII antibodies generated by phage display technology.
Department of Plasma Proteins, CLB, Amsterdam, The Netherlands.
J
J
Voorberg
E N
EN
van den Brink
D001483:Base Sequence; D000939:Epitopes / Q000737:chemistry; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000737:chemistry; D007518:Isoantibodies / Q000737:chemistry; D008969:Molecular Sequence Data; D019151:Peptide Library
D000939:Epitopes; D007128:Immunoglobulin Fragments; D007518:Isoantibodies; D019151:Peptide Library; D005169:Factor VIII